Bio-Rad Laboratories, Inc. (BIO)
| Previous close | 275.60 |
| Open | 275.27 |
| Bid | 276.92 x 1200 |
| Ask | 277.44 x 3000 |
| Day's range | 275.92 - 278.96 |
| 52-week range | 261.59 - 473.50 |
| Volume | |
| Avg. volume | 205,633 |
| Market cap | 7.923B |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Bio-Rad Announces Life Science Group Management Changes
HERCULES, Calif., April 26, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James J. Barry, currently Senior Vice President of Global Manufacturing, to the position of Executive Vice President and President of the Life Science Group, effective May 1, 2024. He succeeds Dr. Simon May, who has announced his decision to leave the company to pursue another professional opportunity.
- Business Wire
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
HERCULES, Calif., April 18, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
- GlobeNewswire
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the c
